Style | Citing Format |
---|---|
MLA | Noori S, et al.. "Naringenin and Cryptotanshinone Shift The Immune Response Towards Th1 and Modulate T Regulatory Cells Via Jak2/Stat3 Pathway in Breast Cancer." BMC Complementary Medicine and Therapies, vol. 22, no. 1, 2022, pp. -. |
APA | Noori S, Nourbakhsh M, Imani H, Deravi N, Salehi N, Abdolvahabi Z (2022). Naringenin and Cryptotanshinone Shift The Immune Response Towards Th1 and Modulate T Regulatory Cells Via Jak2/Stat3 Pathway in Breast Cancer. BMC Complementary Medicine and Therapies, 22(1), -. |
Chicago | Noori S, Nourbakhsh M, Imani H, Deravi N, Salehi N, Abdolvahabi Z. "Naringenin and Cryptotanshinone Shift The Immune Response Towards Th1 and Modulate T Regulatory Cells Via Jak2/Stat3 Pathway in Breast Cancer." BMC Complementary Medicine and Therapies 22, no. 1 (2022): -. |
Harvard | Noori S et al. (2022) 'Naringenin and Cryptotanshinone Shift The Immune Response Towards Th1 and Modulate T Regulatory Cells Via Jak2/Stat3 Pathway in Breast Cancer', BMC Complementary Medicine and Therapies, 22(1), pp. -. |
Vancouver | Noori S, Nourbakhsh M, Imani H, Deravi N, Salehi N, Abdolvahabi Z. Naringenin and Cryptotanshinone Shift The Immune Response Towards Th1 and Modulate T Regulatory Cells Via Jak2/Stat3 Pathway in Breast Cancer. BMC Complementary Medicine and Therapies. 2022;22(1):-. |
BibTex | @article{ author = {Noori S and Nourbakhsh M and Imani H and Deravi N and Salehi N and Abdolvahabi Z}, title = {Naringenin and Cryptotanshinone Shift The Immune Response Towards Th1 and Modulate T Regulatory Cells Via Jak2/Stat3 Pathway in Breast Cancer}, journal = {BMC Complementary Medicine and Therapies}, volume = {22}, number = {1}, pages = {-}, year = {2022} } |
RIS | TY - JOUR AU - Noori S AU - Nourbakhsh M AU - Imani H AU - Deravi N AU - Salehi N AU - Abdolvahabi Z TI - Naringenin and Cryptotanshinone Shift The Immune Response Towards Th1 and Modulate T Regulatory Cells Via Jak2/Stat3 Pathway in Breast Cancer JO - BMC Complementary Medicine and Therapies VL - 22 IS - 1 SP - EP - PY - 2022 ER - |